Markets
CME

Top Research Reports for August 4, 2016

Thursday, August 4, 2016

Today's must-read reports are for Shire (SHPG), Colgate-Palmolive Co. (CL) and CME Group Inc. (CME).

Shire shares have moved up following the quarterly report, with the specialty pharmaceutical operator beating top- and bottom-line estimates guiding higher following the Baxalta acquisition. The analyst likes the company's strong position in the attention deficit hyperactivity disorder (ADHD) market coupled with its recent acquisitions, which is expected to bolster its rare disease portfolio. (You can read the full research report on SHPG here >> )

Zacks Rank # 2 (Buy) rated Colgate Palmolive shares are up more than 12% year-to-date, with the company's improved earnings picture following the quartelry release helping sustain the favorable momentum. The analyst likes the fact that Colgate expects another year of robust organic sales growth on the back of new products across categories and geographical regions, which encouraged it to retain its 2016 outlook. (You can read the full research report on CL here >> )

CME Group is a Zacks Rank # 2 (Buy) rated stock and has gained nearly 14% year-to-date on the back of efforts to expand and cross-sell through strategic alliances, acquisitions, new product initiatives and global presence. In the second quarter, the company witnessed solid revenue growth as well as cost-control induced margin expansion. Notably, CME Group registered a year-over-year increase of 10% in average daily volume for Jul 2016. (You can r ead the full research report on CME here>> )

Other notable reports in today's write-up include Aflac (AFL), Fiserv (FISV) and CBS Corporation (CBS).

You can find all of today's stock research reports here>>> .

Want to see all of today's Zacks Strong Buys?

Today's 5 additions are just the appetizer. You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 stocks free of charge. There is no better place to start your own stock search. Plus you can also access the full list of must-avoid Zacks Strong Sells and other private research. See the stocks free >>.

Sheraz Mian

Director of Research

Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles includeEarnings TrendsandEarnings Preview. He also provides weekly commentary toZacks Premiumsubscribers and manages theZacks Focus Listand Top 10 portfolios.

If you want an email notification each time Sheraz publishes a new article, pleaseclick here >>

Today's Must Read

Shire (SHPG) Beats on Q2 Earnings & Revenues, Updates View

Colgate (CL) Retains View on Q2 Earnings Beat, Sales Lag

CME Group's (CME) July Average Daily Volume Increases

Featured Reports

Aflac's (AFL) Earnings Beat on Higher Premium, View Intact

A low interest rate in Japan poses headwinds, according to the Zacks analyst.

Fiserv (FISV) Raises 2016 Earnings View Despite Competition Woes

The covering analyst thinks that despite strong competition in the payments industry, Fiserv has been seeing strength with offerings like Mobiliti ASP and DNA.

Xerox (XRX) Aims to Spur Growth via Business Restructuring

Xerox is splitting its BPO business from Document Technology and Document Outsourcing businesses to focus on revenue growth and margin expansion.

International Flavors (IFF) Hikes Dividend Rate by 15%

International Flavors & Fragrances is committed to reward its shareholders handsomely through dividends and share buybacks.

Zions' (ZION) Q2 Earnings Indicates Revenue Growth Ahead

The Zacks analyst believes domestic economic growth should continue to spur loan demand, which will support Zions' revenue improvement.

Genworth (GNW) Beats Q2 Earnings on Solid U.S. Mortgage Insurance

Genworth is intensifying its focus on improving its mortgage insurance and long-term care businesses, streamline business as well as enhance financial flexibility and strength.

Dun & Bradstreet (DNB) Beats on Q2 Earnings and Revenues

The Zacks Analyst feels that D&B's high-margin business model, sale of underperforming operations and acquisitions are positives but competition, weak DNBi business and high debt pose serious threats.

New Upgrades

CBS Corporation (CBS) Looks Firm on Growth Trajectory

The covering analyst believes that increasing subscription-based revenues and higher political advertising spending are likely to boost CBS Corporation's performance in the coming quarters.

Boston Properties' (BXP) Q2 FFO Beats, Revenues Rise

The Zacks analyst thinks higher revenues and portfolio operations aided Q2 results. Its presence in high-rent markets and healthy labor market, are likely to drive it growth further.

IDEXX (IDXX) Tops Q2 Earnings on Balanced Growth, View Up

According to the Zacks analyst, IDEXX's solid earnings in Q2 is backed by robust instrument placement, global lab momentum and test menu expansion. The raised 2016 guidance 2016 also buoys optimism.

New Downgrades

Genomic Health (GHDX) Posts In-Line Q2 Loss, Margins Down

Genomic Health's Q2 loss came in line with the Zacks Estimate, but margins dropped. The Zacks analyst stresses that the sales beat was driven by strong test revenue growth across geographies.

Hess (HES) Weighed Down by Price Concerns

The covering analyst thinks the weak price environment has reduced Hess' ability to generate cash flow. Also, it continues to be dependent on major asset sales to support its capital expenditures

Slow Sales Growth Impacting General Mills' (GIS) U.S. Retail Segment

Like many other U.S. food producers, General Mills has been struggling due to the shift in consumer preference towards natural and organic food according to the Zacks analyst.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

FISERV INC (FISV): Free Stock Analysis Report

CME GROUP INC (CME): Free Stock Analysis Report

COLGATE PALMOLI (CL): Free Stock Analysis Report

CBS CORP (CBS): Free Stock Analysis Report

AFLAC INC (AFL): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CME FISV CBS CL

Other Topics

Stocks